Skip to content

EXAMPLES.md

Latest commit

 

History

History
186 lines (151 loc) · 8.45 KB

EXAMPLES.md

File metadata and controls

186 lines (151 loc) · 8.45 KB

Precision Medicine Stratification - Examples

Example 1: Breast Cancer with BRCA1 Mutation

Input:

Stratify this breast cancer patient: BRCA1 pathogenic variant (c.68_69delAG), ER+/HER2-, stage IIA, age 45, premenopausal. Family history: mother had ovarian cancer.

Expected Analysis Flow:

  1. Disease: Breast carcinoma (EFO_0000305), Category: CANCER
  2. BRCA1 c.68_69delAG -> ClinVar pathogenic (185del AG, founder mutation)
  3. Molecular subtype: Luminal B, BRCA1+
  4. Cancer risk: Stage IIA moderate, BRCA1 high penetrance
  5. PGx: Check CYP2D6 for tamoxifen metabolism
  6. Treatment: Platinum chemo benefit, PARP inhibitor eligible (olaparib/talazoparib)
  7. Guideline: NCCN recommends genetic counseling, PARP inhibitor consideration
  8. Trials: BRCA1+ breast cancer trials, PARP combination trials

Expected Score: ~55-65 (HIGH)

  • Genetic: 30 (pathogenic BRCA1)
  • Clinical: 15 (stage IIA)
  • Molecular: 15 (BRCA1-associated features)
  • PGx: depends on CYP2D6

Key Recommendations:

  • 1st line: Surgery + chemotherapy (platinum-based benefit), endocrine therapy (if CYP2D6 normal: tamoxifen, if PM: aromatase inhibitor + ovarian suppression)
  • Consider: PARP inhibitor (olaparib) per NCCN guidelines for BRCA+ breast cancer
  • Risk-reducing surgery discussion (bilateral mastectomy, BSO)
  • Family genetic counseling recommended

Example 2: Type 2 Diabetes with PGx Concern

Input:

Precision medicine stratification: Type 2 diabetes, HbA1c 8.5%, CYP2C19 *2/*2 poor metabolizer, also on clopidogrel for CAD stent placed 3 months ago. Age 62, male, BMI 32, eGFR 65.

Expected Analysis Flow:

  1. Disease: T2D (EFO_0001360) + CAD comorbidity, Category: METABOLIC
  2. Genetic risk: Check T2D GWAS variants (TCF7L2, etc.)
  3. Clinical risk: HbA1c 8.5% = high, CKD stage 2, obesity
  4. CRITICAL PGx: CYP2C19 *2/*2 = poor metabolizer -> clopidogrel INEFFECTIVE
  5. PharmGKB: CYP2C19 PM -> switch to ticagrelor or prasugrel (URGENT)
  6. Comorbidity: T2D + CAD + CKD = high composite risk
  7. T2D treatment: Consider SGLT2 inhibitors (cardio/renal benefit), metformin adjust for eGFR

Expected Score: ~55-65 (HIGH)

  • Genetic: 15 (T2D polygenic risk, no monogenic)
  • Clinical: 25 (HbA1c 8.5, CKD, CAD comorbidity)
  • Molecular: 10 (polygenic T2D)
  • PGx: 8 (CYP2C19 PM - CRITICAL for clopidogrel)

Key Recommendations:

  • URGENT: Switch clopidogrel to ticagrelor 90mg BID or prasugrel 10mg daily (CYP2C19 PM)
  • T2D: SGLT2 inhibitor (empagliflozin/dapagliflozin) for cardio-renal benefit
  • Continue metformin (adjust for eGFR 65)
  • Monitor: HbA1c q3 months, eGFR q6 months, platelet function test

Example 3: NSCLC with Comprehensive Molecular Data

Input:

NSCLC adenocarcinoma patient: EGFR L858R mutation, TMB 25 mut/Mb, PD-L1 TPS 80%, stage IV with brain metastases, age 58, female, never-smoker. No T790M. What is the best treatment strategy?

Expected Analysis Flow:

  1. Disease: NSCLC (EFO_0003060), Category: CANCER, Stage IV
  2. EGFR L858R: Actionable driver mutation -> EGFR TKI eligible
  3. TMB 25: TMB-high -> pembrolizumab eligible (tissue-agnostic)
  4. PD-L1 80%: High PD-L1 -> ICI eligible
  5. Brain mets: Osimertinib has CNS penetration (preferred EGFR TKI)
  6. Conflict resolution: EGFR mutant NSCLC responds poorly to ICI alone
  7. Treatment hierarchy: EGFR TKI first (osimertinib), ICI on progression

Expected Score: ~75-85 (VERY HIGH)

  • Genetic: 25 (EGFR driver mutation)
  • Clinical: 28 (stage IV, brain mets)
  • Molecular: 20 (actionable EGFR + high TMB/PD-L1)
  • PGx: 2 (no specific PGx concern for osimertinib)

Key Recommendations:

  • 1st line: Osimertinib 80mg daily (preferred for EGFR L858R, CNS penetration)
  • 2nd line (on progression): Check T790M resistance. If T790M+: already on osimertinib. If C797S or other: chemotherapy + anti-VEGF
  • 3rd line: Consider ICI-based regimen or clinical trial
  • Brain mets: SRS/WBRT if symptomatic, osimertinib often controls CNS disease
  • Monitor: CT chest/brain q3 months, ctDNA liquid biopsy for resistance

Example 4: Cardiovascular Risk with Pharmacogenomics

Input:

Cardiovascular risk stratification: LDL 190 mg/dL, total cholesterol 280, HDL 42, SLCO1B1*5 heterozygous (rs4149056 TC), family history of MI (father at age 48, brother at age 52). Age 50, male, non-smoker, BP 135/85.

Expected Analysis Flow:

  1. Disease: CAD/FH evaluation (EFO_0001645), Category: CVD
  2. Genetic: Check LDLR, APOB, PCSK9 for familial hypercholesterolemia
  3. LDL 190 + family hx: Possible FH (Dutch Lipid Clinic Score)
  4. ASCVD risk: Calculate based on age, sex, BP, lipids, family hx
  5. PGx: SLCO1B1*5 hetero -> moderate statin myopathy risk (simvastatin most affected)
  6. Treatment: Use rosuvastatin (lower SLCO1B1 interaction) or pravastatin
  7. Consider PCSK9 inhibitor if LDL not at goal with statin alone

Expected Score: ~50-60 (HIGH)

  • Genetic: 20 (family hx, possible FH, pending genetic confirmation)
  • Clinical: 22 (LDL 190, family hx premature CVD, borderline BP)
  • Molecular: 10 (pending FH gene testing)
  • PGx: 5 (SLCO1B1*5 hetero -> statin selection impact)

Key Recommendations:

  • Genetic testing for LDLR, APOB, PCSK9 (FH cascade screening)
  • Statin: Rosuvastatin 20-40mg (preferred over simvastatin/atorvastatin due to SLCO1B1*5)
  • If LDL not at goal (<70mg/dL for high risk): Add ezetimibe, then PCSK9 inhibitor
  • Lifestyle: Mediterranean diet, exercise, BP management
  • Monitor: Lipid panel q6 weeks until at goal, then q6-12 months. CK if muscle symptoms

Example 5: Rare Disease (Marfan Syndrome)

Input:

Evaluate this patient for Marfan syndrome: FBN1 c.4082G>A (p.Cys1361Tyr) variant, tall stature (6'4"), arachnodactyly, aortic root diameter 4.2cm (Z-score 3.5), mild mitral valve prolapse, myopia. Age 28, male.

Expected Analysis Flow:

  1. Disease: Marfan syndrome (Orphanet_558), Category: RARE/MONOGENIC
  2. FBN1 c.4082G>A: Check ClinVar for pathogenicity (cysteine substitution in cbEGF domain)
  3. Phenotype: Meets Ghent criteria (aortic Z>2 + FBN1 mutation = Marfan confirmed)
  4. Aortic risk: 4.2cm root -> monitor closely, surgery if >5.0cm or rapid growth
  5. No PGx relevant for beta-blocker/ARB therapy
  6. Genetic counseling: Autosomal dominant, 50% recurrence risk

Expected Score: ~55-65 (HIGH)

  • Genetic: 30 (pathogenic FBN1 mutation)
  • Clinical: 18 (aortic dilation, MVP, but not yet surgical threshold)
  • Molecular: 12 (cbEGF domain mutation = moderate-severe spectrum)
  • PGx: 0 (beta-blockers/ARBs: no significant PGx)

Key Recommendations:

  • Diagnosis: Confirmed Marfan syndrome (Ghent criteria met)
  • 1st line: Losartan or beta-blocker (atenolol) for aortic root protection
  • Monitoring: Annual echo for aortic root (more frequent if growing), ophthalmology annual
  • Surgery threshold: Aortic root >5.0cm, or growth >0.5cm/year, or family hx of dissection
  • Genetic counseling: AD inheritance, 50% risk to offspring
  • Activity restrictions: Avoid competitive sports, heavy lifting, isometric exercise

Example 6: Alzheimer's Risk Assessment

Input:

Precision medicine risk assessment for Alzheimer's: APOE e4/e4 homozygous, age 55, female, family history of early-onset Alzheimer's (mother at 62, maternal aunt at 65). No symptoms currently. Cognitive screening normal.

Expected Analysis Flow:

  1. Disease: Alzheimer disease (MONDO_0004975), Category: NEUROLOGICAL
  2. APOE e4/e4: Highest genetic risk (10-15x risk vs e3/e3)
  3. Family history: Strong positive (first-degree, early onset)
  4. Check: APP, PSEN1, PSEN2 for familial early-onset AD genes
  5. Currently asymptomatic: Primary prevention window
  6. Emerging therapies: Anti-amyloid antibodies (lecanemab, donanemab) in early AD
  7. PGx: Check CYP2D6 for cholinesterase inhibitor metabolism (future use)

Expected Score: ~60-72 (HIGH)

  • Genetic: 35 (APOE e4/e4 = highest genetic risk)
  • Clinical: 15 (strong family hx, female sex, but currently asymptomatic)
  • Molecular: 15 (APOE genotype + possible additional risk alleles)
  • PGx: 2 (no current medications to evaluate)

Key Recommendations:

  • Risk tier: HIGH (not yet Very High because currently asymptomatic)
  • Prevention: Cardiovascular risk factor control (exercise, diet, BP, diabetes prevention)
  • Monitoring: Cognitive screening annually, consider amyloid PET or CSF biomarkers at age 60
  • Consider: Clinical trial enrollment for AD prevention studies (A4 study type)
  • Genetic counseling: Discuss APOE implications, testing for APP/PSEN1/PSEN2
  • Emerging: Anti-amyloid therapies (lecanemab) if/when MCI develops
  • Lifestyle: Mediterranean diet, aerobic exercise, cognitive engagement, sleep hygiene